Coverage


 
    Stockhead Health and Biotech Investment Guide  
 
    Stocks of the Hour: Kazia Therapeutics, Mesoblast, BHP &Oz Minerals  
 
    ASX edges lower in morning trading, reporting season kicks off: Aus shares down 0.2% at noon  
 
    Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma  
 
    Kazia Therapeutics' promising data on treatment targeting brain metastases to be presented at conference  
 
    Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer  
 
    Tech snaps 4-day winning streak, Iron ore miners rebound: ASX closes 0.8% higher  
 
    Australia trade surplus hits record high, Chalice Mining soars on discovery: ASX up 0.2% at noon  
 
    Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining  
 
    Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer  
 
    Kazia Therapeutics continues to make good progress on cancer treatment assets  
 
    Kazia Therapeutics secures orphan drug designation for treatment of AT/RT tumours with paxalisib  
 
    Stocks of the Hour: Kazia Therapeutics, Westgold Resources &Lake Resources  
 
    Kazia Therapeutics welcomes presentation of positive paxalisib data at international symposium  
 
    Kazia onto next chapter in Phase 2 brain metastases trial  
 
    Kazia Therapeutics’ Phase 2 paxalisib study moves to expansion stage in breast cancer brain metastases cohort  
 
    Kazia Therapeutics’ paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich  
 
    Sector Watch: Healthcare - M&Afever on the cards?  
 
    Nasdaq jumps as Dow falls, Immutep, Antisense, Pushpay, AGL, Star on watch: ASX poised to open lower  
 
    Kazia Therapeutics and its flagship asset have made significant progress against brain cancers: Pitt Street Research  
 
    Kazia Therapeutics wraps up a busy quarter presenting paxalisib data at the AACR annual meeting  
 
    Kazia Therapeutics establishes ‘at the market’ equity program  
 
    Kazia Therapeutics completes Phase 2 study of glioblastoma drug Paxalisib; data to follow at conference  
 
    Kazia Therapeutics encouraged by “promising data” on its cancer pipeline presented at AACR meeting in New Orleans  
 
    Kazia Therapeutics initiates Phase II study of paxalisib for newly diagnosed and recurrent glioblastoma  
 
    Kazia Therapeutics delivers on plans with two promising assets in human trials  
 
    Kazia Therapeutics appoints US-based CFO to assist global market expansion  
 
    Kazia Therapeutics' clinical paxalisib data maintains Speculative Buy rating from Bell Potter  
 
    Kazia Therapeutics (ASX:KZA) announces positive results for brain cancer drug  
 
    ASX up, Berkshire billionaire gives his views on crypto and will BHP benefit from rising iron ore prices?  
 
    Kazia Therapeutics releases positive final data from Phase 2 trial of glioblastoma treatment paxalisib, shares up  
 
    Kazia Therapeutics expands further in North America with Toronto glioblastoma study  
 
    Kazia Therapeutics appoints former Cellectar Biosciences chief medical officer John Friend as new CMO  
 
    Kazia Therapeutics welcomes start of PNOC study in childhood brain cancer, first patient enrolled  
 
    Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial  
 
    Kazia Therapeutics enrols first patient to phase I clinical trial of EVT801 cancer therapy  
 
    Kazia Therapeutics gets boost with ‘buy’ call from Maxim Group and valuation upgrade from Edison  
 
    Kazia Therapeutics’ paxalisib program data garners increased target share price of A$2.83 from Edison  
 
    Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference  
 
    Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 study  
 
    Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial  
 
    Kazia Therapeutics (ASX:KZA) glioblastoma Phase II trial results